Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
IMPEL PHARMACEUTICALS INC (IMPL)
|
Add to portfolio |
|
|
|
| Price: |
$8.11
| | Metrics |
| OS: |
23.7
|
M
| |
|
|
| Market cap: |
$193
|
M
| |
|
|
|
Net cash:
|
$15.2
|
M
| |
$0.64
|
per share
|
|
EV:
|
$177
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($36.2)
|
M
| |
|
|
| EPS |
($2.56)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 |
| Revenues | 12.7 | 12.7 | 0.7 | 0.7 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 1794.0% | 1794.0% | | | | | |
| Cost of goods sold | 6.5 | 6.5 | 0.7 | 0.7 | 0.0 | 0.0 | 0.0 |
| Gross profit | 6.2 | 6.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 48.7% | 48.7% | -3.4% | -3.4% | | | |
| Selling, general and administrative | | 77.9 | | 50.9 | | 17.0 | |
| Research and development | 11.5 | 11.5 | 20.6 | 20.6 | 28.3 | 28.3 | 28.8 |
| General and administrative | 77.9 | | 50.9 | | 17.0 | | 12.8 |
| EBIT | -81.4 | -83.2 | -69.8 | -71.5 | -45.3 | -45.3 | -41.6 |
| EBIT margin | -643.3% | -657.5% | -10447.0% | -10701.5% | | | |
| Pre-tax income | -106.3 | -106.3 | -76.5 | -76.5 | -45.8 | -45.8 | -41.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | | | | |
| Net income | -106.3 | -106.3 | -76.7 | -76.7 | -46.3 | -46.3 | -42.4 |
| Net margin | -840.3% | -840.3% | -11476.8% | -11476.8% | | | |
| |
| Diluted EPS | ($4.53) | ($4.53) | ($5.25) | ($5.25) | ($91.05) | ($91.05) | ($122.07) |
| Shares outstanding (diluted) | 23.4 | 23.4 | 14.6 | 14.6 | 0.5 | 0.5 | 0.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|